# CEFO Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cefo-bio

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.cefobio.com
- Total disclosed funding: $9.7M
- Latest round: Series D (Mar 27, 2023)
- Investors on record: 3

## About

Based in Seoul, South Korea, and founded in 2011, CEFO Co., Ltd., trading under the name CEFO Bio, operates as a company that conducts research and development of stem cell therapy. The company was co-founded by its CEO, Hyunsook Park. In August 2023, CEFO Bio raised KRW 1.2 billion in venture funding from returning investor Multi Asset Global Investments. The company is involved in the commercialization of stem cell therapy. CEFO Bio also provides an extensive selection of items and medications associated with stem cells and tissues, including primary and stem cells, cell growth medium, enzymes, and human adipocyte-conditioned media extract. Their products find application in primary cultured cells, cell culture fluid, collagenase, and cell freezing storage boxes, facilitating researchers in their endeavours to advance regenerative medicine using these resources.

## Funding rounds

- Series D, Mar 27, 2023, $3.1M — SV Investment, Korea Asset Investment Securities
- Series C, Jul 7, 2021, $5.2M — Multi Asset Global Investments, SV Investment
- Series A, Nov 4, 2016, $1.3M — SV Investment

## Investors

- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A, Series C, Series D
- Multi Asset Global Investments — Series C
- Korea Asset Investment Securities (https://capitalatlas.ai/funds/korea-asset-investment-securities) — Series D